Dipankar Bhattacharjee to head Teva's global generics business

Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson

Dipankar Bhattacharjee to head Teva’s global generics business
BS B2B Bureau Jerusalem, Israel
Last Updated : Dec 07 2016 | 10:39 AM IST
Israeli pharma major Teva Pharmaceutical Industries Ltd has appointed Dipankar Bhattacharjee as president and CEO of its global generic medicines group, effective from Monday. Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson, who will step down from his role and remain active with the company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition. Bhattacharjee will be based in the US.

As president and CEO of Teva Generics Europe, Bhattacharjee has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business. Under his leadership, Teva’s European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe. He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches.

Dipankar Bhattacharjee joined the Israeli firm as general manager of Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including vice president commercial in both Europe and Asia-Pacific regions and corporate vice president and president, Asia Pacific Region. He began his career at Nestle SA and Bank of America. Bhattacharjee received his BA degree in economics from St. Stephens College, University of Delhi, and his Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.

“Teva will benefit from Dipankar’s extensive experience in generics and specialty medicines, his financial and operational expertise and his deep understanding and appreciation for Teva’s culture of innovation and our outstanding people. As we continue to focus on integrating and realizing the value of the Actavis Generics transaction, which is progressing according to plan, Dipankar and his team will focus on generating organic growth through new launches and replenishing the pipeline through our industry-leading R&D, and drive efficiencies across the generics organisation,” said Erez Vigodman, president and chief executive officer, Teva.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 07 2016 | 10:33 AM IST

Next Story